Search results

Dear friends and partners of Sentio! Welcome to Sentio Days 2025. We are planning for a lunch-to-lunch meeting and an evening dinner. The first day will be open to everyone who would like to know more about Sentio - and on the second day, we the partners, will make plans for our future activities with a focus on actions in the coming year. We look forward to seeing you in Lund for exciting discuss

https://www.sentio.lu.se/article/sentio-days-2025-welcome-lund-20-21-march - 2026-10-27

In a collaboration highlighting efforts to integrate advanced sensors into industrial equipment for real-time optimization and sustainability, researchers from Lund University partnered with Alfa Laval. Together they participated in a hands-on workshop to assemble a gasketed heat exchanger, one of the key industrial elements within the Sentio Competence Centre. A team of researchers from Lund Univ

https://www.sentio.lu.se/article/sentio-strong-start-hands-on-workshop-alfa-laval - 2026-10-27

On Friday 22 November, the Sentio partner IUC Syd (Industrial Development Centre South) organized Skåne Industry Day focusing on sustainability, efficiency and Lean manufacturing. Christina Windmark was there representing Sentio. During the Skåne Industry Day several companies shared their journey on how to become more efficient and include sustainability in their decisions and development. They a

https://www.sentio.lu.se/article/sentio-participated-skane-industry-day-1 - 2026-10-27

In mid-December Sentio visited our partner Elitkomposit in Uddevalla. It was a great opportunity for partners, senior researchers and PhD-students to really understand how sophisticated products are designed and manufactured in different composite materials. With refined production methods of composites it is possible to get past the limits of conventional materials and in mid-December Sentio had

https://www.sentio.lu.se/article/site-visit-elitkomposit-resulting-prototype-zero - 2026-10-27

It was truly great to meet all partners at the Sentio Days 2025 in Lund. Thanks for coming and contributing to such a creative and inspiring meeting! Sentio Days 2025 was arranged on the 20-21 March at the newly inaugurated facilities of LINXS Institute of X-ray and neutron science at the Loop in Science Village, Lund.The first day was open to anyone interested in knowing more about Sentio - and o

https://www.sentio.lu.se/article/sentio-days-2025-0 - 2026-10-27

The very first Sentio PhD-course "Sensors for sustainable production" has been kicked off. Our students are now looking forward to an autumn filled with team-working, lectures, literature reviews, study visits and probably some more cups of coffee. The aim is to equip our PhD students with comprehensive knowledge of sensor technologies and their integration into sustainable manufacturing systems.

https://www.sentio.lu.se/article/sentio-phd-course-kicked - 2026-10-27

Emelie Haettner, PhD-student in Sentio, reports back from a promising first survival test performed at Sandvik Coromant in Västberga. The unprotected semiconductor microstructures that were printed on tool inserts managed to survive the rough cutting process in the workshop. The results are promising for developing sensors that will work under such extreme conditions. Why did you go to Sandvik Cor

https://www.sentio.lu.se/article/rough-survival-test-sandvik-coromant - 2026-10-27

Daniel Benoit moved from Canada to Sweden to take on the role as the new director for MoRe-Lab. Click below to read the full interview with Daniel Benoit:In EnglishIn Swedish

https://www.more-lab.lu.se/article/new-more-lab-director-daniel-benoit - 2026-10-27

A donor who wishes to remain anonymous has donated SEK 7.5 million to the Faculty of Medicine and the Movement & Reality Lab, an experimental health science test environment for full-scale studies of movement, activity and behavior. Read the full article here (new tab, Swedish)

https://www.more-lab.lu.se/article/multi-million-donation-more-lab-lund-university - 2026-10-27

Read the full news article with questions for Kiran Maini Gerhardsson, who wrote the study together with Steven Schmidt and Susanne Iwarsson. (New window, article in Swedish)Read the scientific article here (new window) 

https://www.more-lab.lu.se/article/first-more-lab-study-published - 2026-10-27

The other day, Vice-Chancellors from several Swedish universities were at a conference in Lund and took the opportunity to visit Medfak with their host, Vice-Chancellor Erik Renström. Read the full article on Intramed by clicking here. 

https://www.more-lab.lu.se/article/vice-chancellors-visiting-more-lab - 2026-10-27

On November 19th a group of 40 members of RPG visited MoRe-Lab to learn more about past, future and ongoing research related to healthy ageing.        

https://www.more-lab.lu.se/article/rpg-visits-more-lab - 2026-10-27

In a new Swedish study by Lund University on comorbidities in osteoarthritis, researchers studied if people with osteoarthritis are at an increased risk for cancer compared to people without osteoarthritis. The study focused on the four most common cancer types, lung, colon, breast, and prostate cancer. Researchers found no differences in the risk of being diagnosed with colon cancer if you had os

https://www.arthritisportal.lu.se/article/oa-linked-cancer - 2026-10-27

Previous studies from Iceland have shown how osteoarthritis is often inherited and can be traced back several generations. A gene (genetic predisposition) is a segment of DNA containing hereditary information and is inherited from our biological parents. A new international study published in the high-ranking scientific journal Cell has discovered that a large number of genes are associated with o

https://www.arthritisportal.lu.se/article/your-genes-play-part-development-oa-and-perceived-joint-pain - 2026-10-27

Devil's Claw (Harpagophytum procumbens) is a plant in the sesame family native South Africa that has long been used as a herbal medicine to treat a number of different diseases. The plant is believed to be able to reduce joint pain and joint stiffness as it is said to have analgesic and anti-inflammatory properties. However, the actual properties of devil's claw are yet not fully understood. There

https://www.arthritisportal.lu.se/article/devils-claw-herbal-medicine-continued-uncertain-effect-oa-pain - 2026-10-27

Osteoarthritis has been described as the 15th most common cause of so-called “years lived with disability” (YLDs) in the world, which is a measure used to shed light on the burden of various diseases on society. According to the researchers, the economic costs caused by the disease correspond to about 1-2.5% of the gross domestic product (GDP) in most countries. A new article from a group of Ameri

https://www.arthritisportal.lu.se/article/global-burden-osteoarthritis - 2026-10-27

In a new Swedish study by Lund University, researchers looked at how common it is with comorbidities in osteoarthritis of the knee and/or hip. The study was published in the American journal Arthritis Care & Research. The study analyzed data collected from the province of Scania's population between the years 1998 and 2017. Newly diagnosed osteoarthritis patients were at a slightly higher risk of

https://www.arthritisportal.lu.se/article/common-comorbidities-osteoarthritis - 2026-10-27

Earlier in October, we reported on a research study that showed that platelet-rich plasma (PRP) injections for treating osteoarthritis of the knee did not have a better effect on OA symptoms than placebo. Last week, results from a new study on PRP were published. The researchers concluded that PRP injections had no effect on ankle OA compared to placebo. The Dutch study included 100 ankle OA patie

https://www.arthritisportal.lu.se/article/effect-prp-ankle-oa-no-better-placebo - 2026-10-27

The painkiller tanezumab was not approved by the European Medicine's Agency. At the beginning of 2021, news came that tanezumab, a new pain medication, would be launched in the US and Europe.  However, in March, tanezumab suffered a setback in the United States when the US Food and Drug Administration rejected the drug for osteoarthritis pain. There was continued uncertainty about the launch of th

https://www.arthritisportal.lu.se/article/not-approved-eu-another-setback-drug-tanezumab - 2026-10-27

Tramadol is an increasingly common drug prescribed for pain. Tramadol is a synthetic opioid (manufactured in a lab) that differs somewhat in its chemical structure compared to the natural opioid codeine. Other opioids include morphine and heroin. All opioids have analgesic properties and are extremely addictive. In a new study based on primary care data from Spain, the risks of a number of side ef

https://www.arthritisportal.lu.se/article/many-risks-painkiller-tramadol - 2026-10-27